Recognizing the complexities of co-prescriptions and life-style factors in opioid agonist treatment: A response from Eleni Domzaridou, Matthew J. Carr, Tim Millar, Roger T. Webb and Darren M. Ashcroft

Addiction. 2024 May;119(5):967-968. doi: 10.1111/add.16447. Epub 2024 Feb 5.

Eleni Domzaridou^{1

2}, Matthew J Carr^{1

2}, Tim Millar³, Roger T Webb^{1

3}, Darren M Ashcroft^{1

2}

¹ National Institute for Health and Care Research Greater Manchester Patient Safety Research Collaboration, University of Manchester, Manchester, UK.
² Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
³ Centre for Mental Health and Safety, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

No abstract available

Keywords: antipsychotics; benzodiazepines; gabapentinoids; non‐fatal overdose; opioid agonist treatment; z‐drugs.

Publication types